Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference

Group 1 - Altimmune, Inc. will participate in the H.C. Wainwright 8th Annual MASH Virtual Conference with CEO Vipin Garg and CMO Scott Harris presenting [1] - The conference is scheduled for October 7, 2024, at 11:30 a.m. EDT and will be available via webcast [1] - Altimmune is a clinical-stage biopharmaceutical company focused on next-generation peptide-based therapeutics [2] Group 2 - The company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist aimed at treating obesity and metabolic dysfunction-associated steatohepatitis (MASH) [2]